TransCelerate BioPharma INTRODUCES NEW SUBSIDIARY

Trending now: Six biopharmaceutical companies launch subsidiary with first initiative-toxicology data sharing.

TRANSCELERATE BIOPHARMA has launched BioCelerate, a new subsidiary that aims to improve efficiencies in preclinical research. The six initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novo Nordisk, and Shionogi. Each of these organizations are also member companies of TransCelerate BioPharma, a condition for participation in BioCelerate, and will lead the first initiative, Toxicology Data Sharing, which will enable access to a broader cross-company set of toxicology data.


Dr. Dalvir Gill

"TransCelerate's commitment to collaboration has laid the foundation for the creation of BioCelerate," says Dalvir Gill, Ph.D., CEO, TransCelerate BioPharma. "It is because of TransCelerate's successful track record in the clinical development space that a subset of its members have decided to leverage that infrastructure, governance model and methodologies for preclinical research. BioCelerate, like TransCelerate, will focus on pragmatic and tangible solutions to common challenges with the end goal of improving drug development efficiency and bringing new medicines to patients faster. The organization will seek to actively collaborate with multiple stakeholders to enhance the resources dedicated to solving these issues and will also ensure visibility of projects to regulatory agencies."

Ogilvy CommonHealth Worldwide Agency to Address Needs of Smaller Clients


Peter Rooney

Ogilvy CommonHealth Worldwide (OCHWW), the health behavior change specialists of Ogilvy & Mather and a WPP company, has launched a new agency — Ogilvy CommonHealth Nano — created to serve the distinct brand needs of small to midsize healthcare companies.

Ogilvy CommonHealth Nano is a full-service, integrated healthcare agency with services and processes that provide smaller client companies with customized marketing experiences across the landscapes of pharma, biotech, devices, diagnostics, OTCs, and digital health. Leading the agency is newly appointed general manager Peter Rooney.

"As we continue to diversify our client roster, we recognize the need to adapt our business approach with these small to midsize healthcare companies," says Darlene Dobry, an OCHWW managing partner. "These companies are often very nimble and efficient, streamlined in their decision-making, and open to new and untested ideas."

INC Research Launches Program to Strengthen Collaboration with Clinical Research Sites


Dr. Clare Grace

INC Research Holdings, a global Phase I to IV contract research organization, has launched the Catalyst program to strengthen collaborations with clinical research sites, in turn enhancing patient focus and optimizing study delivery to drive improved predictability of clinical trials and reduce development timelines for biopharmaceutical customers worldwide.

INC's Catalyst program includes two components — the Catalyst Site Network and the Catalyst Community — which focus on developing stronger collaborations with clinical research sites across the globe.

"Sites play an essential role in bringing new therapies to market for patients," says Clare Grace, Ph.D., VP, site and patient access. "By involving them early on and making them a partner in the clinical development process, studies start more quickly and run more predictably."

On the Shelves



Orphan Drugs: A Global Crusade, the memoir of Abbey Meyers, founder and past president of the National Organization for Rare Disorders (NORD), has been released to bring to light the hard work and commitment of orphan drug crusaders.

This book is Ms. Meyers' effort to document the issues that led to enactment of the Orphan Drug Act of 1983 in the U.S. She talks of the struggle of patient organizations, medical researchers, and the American public. Eventually many industrialized countries enacted their own orphan drug laws, which spurred scientific and industrial progress that resulted in new treatments and cures for millions of rare disease patients throughout the world.

GHG Greyhealth Group Acquires The Lathe

The Lathe, a New York-based digital design and development company focused exclusively on helping healthcare organizations use technologies to connect patients, caregivers, and professionals, has been acquired by ghg greyhealth group, a healthcare communications services company.

"The Lathe has pioneered innovative mobile solutions in chronic and rare disease for many major pharmaceutical companies," says Lynn O'Connor Vos, CEO of ghg. "Together, we will create novel solutions for key health stakeholders."

Bioclinica Launches Postapproval Service

Bioclinica, a specialty clinical trials services and technology provider, has launched its newest service line offering. The Post-Approval Research division of its Global Clinical Research business segment was created to meet the rapidly growing needs of the post-approval research industry.

"At Bioclinica, we understand the fundamental differences between the design and conduct of post-approval studies and those performed prior to approval," says Dr. John Hubbard, president and CEO, Bioclinica. PV



PharmaVOICE 100 *Celebration*

September 15, 2016

Against the backdrop of New York City's elegant and high-tech Alexandria Center for Life Science, This year's **PharmaVOICE 100 Celebration** will bring together the most inspirational and influential leaders from across all sectors of the life-sciences industry, for much-needed collaboration through sharing ideas, insights, and business perspectives, while enjoying the opportunity to expand personal and professional networks.

Register online
www.pharmavoice.com/pv100-celebration